Tag: ISMP QuarterWatch
-
Number Of Nuplazid Patient Deaths Reported To FDA In Just The Past Two Years Causes Alarm In Drug Safety Circles
This Relatively New Parkinson’s Disease Drug Already Been Implicated In Hundreds Of Death Cases, While Only Being On Market Since 2016 (Posted by Tom Lamb at DrugInjuryWatch.com) Two years ago the FDA…
-
New Heart Failure Drug Entresto Apparently Has Safety Signal For Hypotension (Low Blood Pressure) Side Effect
Will Recent ISMP QuarterWatch Report Prompt FDA Regulatory Action, Including Possible Drug Label Change By Novartis? (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA approved Entresto™ (sacubitril and valsartan) tablets in July…
-
Invokana Cases Involving Diabetic Ketoacidosis And Kidney Problems Reported As Adverse Drug Events To FDA
Farxiga, Jardiance, And Other New SLGT2 Diabetes Drugs Also Cause Metabolic Acidosis As Well As Other Serious Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between…
-
Some Patients Who Stopped Taking Cymbalta Have Suffered From Extended And Severe Withdrawal Reactions Without Warning
Cymbalta Discontinuation Syndrome / Symptoms Include "Brain Zaps", Extreme Mood Swings (anger, irritability), And Neurological Or Physical Problems (Posted by Tom Lamb at DrugInjuryWatch.com) While generally thought of as an antidepressant drug, Cymbalta (duloxetine) from Eli Lilly…
-
Pradaxa Adverse Drug Events (ADEs) Result In Death More Often Than Other Anticoagulants / Blood Thinners ADE Reports
Again In 2012, Pradaxa (Dabigatran) Had Dubious Distinction Of Being Ranked First For Direct FDA Reports Of Adverse Events (Posted by Tom Lamb at DrugInjuryWatch.com) The October 2013 edition of ISMP QuarterWatch, Data from 2012…
-
Pradaxa Hemorrhage Cases May Occur In Oldest Patients Due To Age-Related Decline In Renal Function
QuarterWatch 2011 Quarter 2: More Pradaxa Adverse Events Reported Than Any Other Regularly Monitored Drug (Posted by Tom Lamb at DrugInjuryWatch.com) The developing drug safety controversy involving the anticoagulation drug Pradaxa (dabigatran) has been…